Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...

We welcome two special guests, Dr. Stacy Lindborg, and Dr. Premal Thaker, to discuss the results of the OVATION 2 Study and ...

The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...

The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.

Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma, discussed 'Breakthroughs in Lung Cancer Treatment for Never Smokers,' including the novel AI-assisted drug candidate, ...

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we will explore the ...

The FDA has approved the Altius® System, an innovative device for managing chronic pain in lower limb amputees. Utilizing direct electrical nerve stimulation, the device proved effective in reducing ...

The FDA has approved Illumina's TruSight Oncology Comprehensive test as a companion diagnostic for two cancer indications. This biomarker test profiles over 500 genes in solid tumors, aiding in the ...

The application for nipocalimab was submitted to the FDA for the treatment of generalized myasthenia gravis (gMG), following promising results from the Phase 3 Vivacity-MG3 study. This ...

The first human trial of BNT116, an mRNA-based lung cancer vaccine, has started, and the first patient received the treatment at UCLH. Developed by BioNTech, the vaccine targets non-small cell lung ...

The novel cancer drug, PT217, has received FDA Orphan Drug Designation for treating neuroendocrine carcinoma (NEC). PT217, which targets DLL3 and CD47, offers new hope for NEC patients, typically ...